## Management of Ureteric Stones: Evidence-Based Approach ### Clinical Context The patient has a small (6 mm) ureteric stone at the pelvic brim with no fever, normal renal function, and no obstruction — ideal candidate for conservative management. ### Correct Statements **Key Point:** Expectant management is appropriate for uncomplicated stones <6 mm because the spontaneous passage rate is 68–100% depending on size and location. Analgesia (NSAIDs or opioids), hydration, and follow-up imaging at 4 weeks are standard. **High-Yield:** ESWL is absolutely contraindicated in the presence of untreated UTI or urosepsis because shock waves can disseminate bacteria and cause septic shock. Infection must be treated first, then stone managed. **Clinical Pearl:** For distal ureteric stones >10 mm, ureteroscopic removal (URS) is preferred over ESWL because: - Higher success rate (>95% vs 70–80%) - Lower re-treatment rate - Distal stones have lower ESWL success due to pelvic anatomy and bone interference ### Why Option 3 (Alpha-Blockers) is INCORRECT | Evidence | Finding | Implication | |---|---|---| | **AUA/EAU Guidelines** | Alpha-blockers NOT recommended for routine stone passage | No Level 1 evidence | | **Meta-analyses** | Mixed/weak evidence; effect size small | Not standard of care | | **Mechanism** | Theoretically relax ureteric smooth muscle | Benefit unproven in RCTs | | **Current Status** | Removed from major guidelines (2019+) | NOT recommended adjunct | **Key Point:** While alpha-blockers (tamsulosin) were once proposed for stone passage, recent high-quality RCTs and meta-analyses (including SUSPEND trial) have shown **no significant benefit** in reducing time to passage or improving passage rates. They are **NOT recommended** as routine adjunctive therapy by current AUA/EAU guidelines (2019 onwards). **Warning:** This is a common examination trap — older textbooks mention alpha-blockers, but modern evidence does not support their use. ### Management Algorithm for This Patient ```mermaid flowchart TD A[6 mm right ureteric stone<br/>at pelvic brim]:::outcome --> B{Signs of infection<br/>or obstruction?}:::decision B -->|Yes| C[Urgent decompression<br/>+ antibiotics]:::urgent B -->|No| D[Expectant management]:::action D --> E[NSAIDs + hydration<br/>+ analgesia PRN]:::action E --> F[Follow-up NCCT<br/>at 4 weeks]:::action F --> G{Stone passed?}:::decision G -->|Yes| H[Metabolic workup<br/>+ prophylaxis]:::action G -->|No| I{Stone >6 mm<br/>or symptomatic?}:::decision I -->|Yes| J[URS or ESWL]:::action I -->|No| K[Continue expectant<br/>management]:::action ``` ### Summary Table: Ureteric Stone Management by Size | Stone Size | Location | First-Line | Success Rate | Notes | |---|---|---|---|---| | <6 mm | Any | Expectant | 68–100% | Depends on location; proximal lower | | 6–10 mm | Proximal/mid | Expectant or ESWL | 50–90% | ESWL preferred if symptomatic | | 6–10 mm | Distal | URS | >95% | Better than ESWL due to anatomy | | >10 mm | Proximal/mid | ESWL or URS | 70–95% | ESWL first-line if suitable | | >10 mm | Distal | URS | >95% | URS preferred (higher success) | [cite:Smith's Urology 19e Ch 35; AUA Guidelines on Management of Ureteral Calculi 2019]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.